CLRB stock forecast
Our latest prediction for Cellectar BioSciences, Inc.'s stock price was made on the Nov. 30, 2018 when the stock price was at 2.23$.
In the short term (2weeks), CLRB's stock price should outperform the market by 5.21%. During that period the price should oscillate between -9.99% and +17.34%.
In the medium term (3months), CLRB's stock price should outperform the market by 8.30%. During that period the price should oscillate between -23.88% and +51.03%.Get email alerts
About Cellectar BioSciences, Inc.
Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma; CLR 125, which intends to treat micro metastatic disease; CLR 124 which could detects tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded in June,1996 and is headquartered in Florham Park, NJ.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -5.23$ per share.
The book value per share is 1.24$
Three months stock forecastNov. 30, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|